XML 33 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Segment Data
 6 Months Ended
Jun. 28, 2019
Segment Reporting [Abstract]  
Segment Data
16.
Segment Data
As part of the May 28, 2019 update to the Company's planned separation described within Note 1, the Company's two reportable segments were realigned and are further described below:
•
Specialty Brands includes innovative specialty pharmaceutical brands (inclusive of Amitiza); and
•
Specialty Generics includes niche specialty generic drugs and APIs.
All prior period segment information has been reclassified to reflect the realignment of the Company's reportable segments on a comparable basis. Refer to Note 18 for an update on the Company's plans for the Specialty Generics business.
Selected information by reportable segment was as follows:

Three Months Ended
 
Six Months Ended

June 28,
2019
 
June 29,
2018
 
June 28,
2019
 
June 29,
2018
Net sales:
 
 
 
 
 
 
 
Specialty Brands
$
627.8

 
$
631.7

 
$
1,232.0

 
$
1,204.3

Specialty Generics
195.5

 
193.8

 
381.9

 
376.5

Net Sales
$
823.3

 
$
825.5

 
$
1,613.9

 
$
1,580.8

Operating (loss) income:
 
 
 
 
 
 
 
Specialty Brands
$
321.4

 
$
265.2

 
$
596.9

 
$
506.4

Specialty Generics
33.9

 
43.1

 
58.3

 
78.2

Segment operating income
355.3

 
308.3

 
655.2

 
584.6

Unallocated amounts:
 
 
 
 
 
 
 
Corporate and unallocated expenses (1)          
(36.4
)
 
(12.5
)
 
(82.2
)
 
(56.5
)
Intangible asset amortization
(216.6
)
 
(184.3
)
 
(439.4
)
 
(362.3
)
Restructuring and related charges, net
0.2

 
(58.8
)
 
(4.0
)
 
(87.0
)
Non-restructuring impairments
(113.5
)
 
—

 
(113.5
)
 
—

Separation costs (2)
(18.9
)
 
—

 
(30.6
)
 
—

Operating (loss) income (3)
$
(29.9
)
 
$
52.7

 
$
(14.5
)
 
$
78.8



(1)
Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segment.
(2)
Represents costs incurred related to the separation of the Company's Specialty Generics segment, inclusive of rebranding costs, which are included in SG&A.
(3)
The amount of operating loss included in the Company's unaudited condensed consolidated statement of income for the three and six months ended June 29, 2018 related to the Sucampo Acquisition was $37.0 million and $67.7 million, respectively. Included within these results were $17.9 million and $27.0 million of amortization associated with intangibles recognized from this acquisition and $31.5 million and $46.5 million of expense associated with fair value adjustments of acquired inventory for the three and six months ended June 29, 2018, respectively.

Net sales by product family within the Company's reportable segments were as follows:
 
Three Months Ended
 
Six Months Ended
 
June 28,
2019
 
June 29,
2018
 
June 28,
2019
 
June 29,
2018
Acthar Gel
$
266.4

 
$
293.2

 
$
490.3

 
$
537.0

Inomax
139.7

 
131.0

 
290.8

 
270.8

Ofirmev
90.5

 
85.6

 
186.1

 
167.6

Therakos
60.9

 
56.8

 
122.7

 
114.2

Amitiza (1)
52.0

 
48.0

 
105.0

 
71.0

BioVectra
13.9

 
11.3

 
26.3

 
21.8

Other
4.4

 
5.8

 
10.8

 
21.9

Specialty Brands
627.8

 
631.7

 
1,232.0

 
1,204.3

 
 
 
 
 
 
 
 
Hydrocodone (API) and hydrocodone-containing tablets
18.1

 
16.9

 
35.5

 
30.8

Oxycodone (API) and oxycodone-containing tablets
19.6

 
13.1

 
36.1

 
29.7

Acetaminophen (API)
48.4

 
51.7

 
94.6

 
101.1

Other controlled substances
98.6

 
99.5

 
192.8

 
188.5

Other
10.8

 
12.6

 
22.9

 
26.4

Specialty Generics
195.5

 
193.8

 
381.9

 
376.5

Net Sales
$
823.3

 
$
825.5

 
$
1,613.9

 
$
1,580.8


(1)
Amitiza consists of both product net sales and royalties. Refer to Note 3 for further details on Amitiza's revenues.